PGD3 is produced by the metabolism of EPA via the COX pathway.{1144} It is equipotent to PGD2 in decreasing systemic blood pressure in rats and in decreasing intraocular pressure in rabbits.{1139,1138,1225} However, it is 3-5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation.{1139}